HK Stock Market Move | Joinn Laboratories (06127) surged over 11% as the company significantly raised its earnings forecast for the first half of the year, with positive changes in the fair value of biological assets becoming a core driver.

Joinn Laboratories (06127) rose over 11%, with a current increase of 11.42%, trading at HK$27.32, and a transaction volume of HK$334 million. Recently, Joinn Laboratories released its half-year performance forecast for 2026. According to China Post Securities, in the first half of 2026, the company expects to achieve operating revenue of approximately HK$669 million to HK$739 million (year-on-year growth of 0% to 10.5%) and a net profit attributable to shareholders of about HK$600 million to HK$900 million (year-on-year growth of 884.9% to 1377.4%). The company's net profit excluding non-recurring items is expected to range from HK$561 million to HK$842 million (year-on-year growth of 2334.2% to 3551.3%). China Post Securities believes that the positive changes in the fair value of biological assets are the core driver of Joinn Laboratories' performance surge this period. In H1 2026, the fair value changes of the company's biological assets are expected to contribute a net profit of about HK$703 million to HK$777 million, a substantial increase from HK$88 million in the same period of 2025. As a Contract Research Organization (CRO) with its own breeding base for non-human primate experimental models, the advantage of population resources not only ensures the supply chain security of its own non-clinical evaluation business but also translates directly into performance flexibility through fair value reassessment.